Thread - Patent Press Release
Here is the press release regarding the patent announcement.
==============================================================
Zonagen Receives Lowrey Patent for Vasomax
Business Wire - March 25, 1998 10:41
---------------------------------------------------------------
THE WOODLANDS, Texas--(BW HealthWire)--March 25, 1998--Zonagen, Inc. (NASDAQ:ZONA)(PCX:ZNG) today announced that the U.S. Patent and Trademark Office has issued Patent Number 5,731,339 (the Lowrey Patent) for its proprietary formulation of Vasomax(TM), which was licensed worldwide to Schering-Plough Corporation (NYSE:SGP) in November 1997 for Male Erectile Dysfunction (MED).
The Lowrey Patent describes new rapidly disintegrating oral formulations of phentolamine and methods of modulating human sexual response. The Lowrey patent also provides for an on-demand treatment for female sexual dysfunction.
"The Lowrey Patent further enhances Zonagen's proprietary position for Vasomax(TM) by providing both formulation and method-of-use coverage in the treatment of human sexual dysfunction," said Joseph S. Podolski, president and chief executive officer of Zonagen.
In addition to the Lowrey patent, Zonagen also owns the rights to U.S. Patent Number 5,565,466 (the Zorgniotti Patent) which issued in October 1996.
The Zorgniotti Patent is a broad method-of-use patent that provides for improved methods of modulating the human sexual response, in males and females, by administering certain vasodilators, including phentolamine, to the systemic circulation via certain non-invasive routes of administration.
Zonagen, Inc. specializes in the development of products and services for management of reproductive health. The Company's technologies focus on the areas of urology, female health and contraception. Through its wholly owned subsidiary, Fertility Technologies, Inc. (FTI), Zonagen sells devices, instruments and supplies to the fertility specialist and the OB/GYN.
This release contains certain forward-looking statements, including the statements regarding the patents and proprietary rights of the Company, clinical investigation, timing, approval and commercialization of products that involve risks and uncertainties. Actual events or results may differ from the company's expectations as a result of the factors contained under the caption "Patents and Proprietary Information" in the Company's Annual Report on Form 10-K, as amended, for the year ended Dec. 31, 1996 and in the Company's Prospectus dated July 22, 1997 and other risk factors identified in the Company's reports and registration statements filed with the U.S. Securities Exchange Commission.
CONTACT: Zonagen Inc.
Jean Anne Mire, 281/367-5892
==================================================================== |
